Detalles de la búsqueda
1.
Dose-response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuroendocrine tumor liver metastases.
Eur J Nucl Med Mol Imaging
; 49(5): 1700-1710, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34873638
2.
Prophylactic Medication during Radioembolization in Metastatic Liver Disease: Is It Really Necessary? A Retrospective Cohort Study and Systematic Review of the Literature.
Diagnostics (Basel)
; 13(24)2023 Dec 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38132236
3.
Baseline Imaging Derived Predictive Factors of Response Following [177Lu]Lu-PSMA-617 Therapy in Salvage Metastatic Castration-Resistant Prostate Cancer: A Lesion- and Patient-Based Analysis.
Biomedicines
; 10(7)2022 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35884878
4.
Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy.
EJNMMI Res
; 12(1): 7, 2022 Feb 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35107642
5.
A Rapid and Safe Infusion Protocol for 177Lu Peptide Receptor Radionuclide Therapy.
J Nucl Med
; 62(6): 816-822, 2021 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33246981
6.
Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study.
Eur J Hybrid Imaging
; 5(1): 22, 2021 Dec 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34881405
7.
Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial).
Trials
; 21(1): 141, 2020 Feb 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32024533
Resultados
1 -
7
de 7
1
Próxima >
>>